enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)
enGene Holdings Inc. (Nasdaq: ENGN, or enGene or the Company), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as...